The short answer: Angiosarcoma is a rare, aggressive cancer arising from blood vessel or lymphatic endothelium. It can arise on the scalp/face (cutaneous), in the breast (post-radiation), in the liver, heart, or elsewhere. Advanced angiosarcoma has limited treatment options and requires palliative care focused on managing bleeding, skin lesions, and the specific complications of this vascular tumor.

What to Expect With Angiosarcoma End-of-Life Care

Angiosarcoma is one of the rarest and most aggressive soft tissue sarcomas, arising from vascular (blood vessel) or lymphatic endothelial cells. It accounts for approximately 1-2% of all sarcomas. The prognosis is poor even for localized disease; advanced angiosarcoma has limited treatment options and typically requires early palliative care planning.

Types of Angiosarcoma and Their Locations

Cutaneous angiosarcoma (scalp/face): The most common form — arising on the scalp and face of elderly patients, often presenting as purple-reddish bruise-like areas. Spreads locally and to lymph nodes and lungs.

Breast angiosarcoma: Can arise spontaneously or (more commonly) as a late complication of breast radiation therapy. Post-radiation angiosarcoma has particularly aggressive behavior.

Hepatic angiosarcoma: Arising in the liver; rapidly progressive with symptoms of liver failure.

Cardiac angiosarcoma: Extremely rare; arises from the heart, typically the right atrium; causes arrhythmia, heart failure, and pericardial effusion.

Treatment Trajectory

Surgery is the primary treatment for localized angiosarcoma. Chemotherapy (paclitaxel, which has specific activity in angiosarcoma) and anti-angiogenic agents are used for advanced disease. Immunotherapy (pembrolizumab) may benefit some patients. When treatment stops working, the transition to palliative care should be early and well-planned.

Key Symptoms to Manage

Bleeding: Angiosarcoma is a vascular tumor and prone to significant spontaneous bleeding, especially cutaneous scalp angiosarcoma. Wound management, local hemostatic agents, and palliative radiation to control bleeding are essential.

Wound care: Skin lesions can be large, fungating, and odor-producing. Specialized wound nurses, odor-controlling dressings, and palliative radiation provide relief.

Cardiac symptoms: Cardiac angiosarcoma causes pericardial effusion (fluid around the heart), arrhythmias, and heart failure requiring specific management.

Liver failure symptoms: Hepatic angiosarcoma causes jaundice, ascites, fatigue, and coagulopathy.

The Emotional Impact of Rarity

Angiosarcoma's rarity creates profound isolation — most oncologists have seen only a handful of cases. Patients may struggle to find specialists, feel that their doctors don't know their disease well, and have difficulty finding peer support. ASCO's SARC (Sarcoma Alliance for Research through Collaboration) and Sarcoma Foundation of America provide disease-specific resources.

Frequently Asked Questions

What is angiosarcoma?

Angiosarcoma is a rare, aggressive cancer arising from vascular or lymphatic endothelial cells — the cells lining blood vessels and lymphatic vessels. It most commonly arises on the scalp and face of elderly patients, in the breast (especially post-radiation), in the liver, or occasionally in the heart. It is extremely rare (approximately 1-2% of soft tissue sarcomas) and has a poor prognosis even with treatment.

What are symptoms of advanced angiosarcoma?

Advanced angiosarcoma symptoms depend on location: scalp/face angiosarcoma causes enlarging purple-reddish skin lesions, spontaneous bleeding, and lymph node spread; breast angiosarcoma causes a rapidly enlarging mass; hepatic angiosarcoma causes right upper quadrant pain, jaundice, and liver failure symptoms; cardiac angiosarcoma causes shortness of breath, irregular heartbeat, and signs of right heart failure.

Why is paclitaxel used for angiosarcoma?

Paclitaxel (Taxol) has specific anti-tumor activity in angiosarcoma beyond its general chemotherapy effects, thought to be due to its anti-angiogenic properties that specifically target the blood vessel-derived tumor cells. It is the most commonly used first-line agent for advanced angiosarcoma, with response rates of approximately 30-45%. Weekly dosing is typically preferred.

How is bleeding managed in scalp angiosarcoma?

Bleeding from scalp angiosarcoma is managed with local pressure and hemostatic dressings (calcium alginate, oxidized cellulose), palliative radiation which can significantly reduce tumor vascularity and bleeding, topical agents (tranexamic acid dressings), embolization procedures for significant bleeding, and ultimately systemic antifibrinolytics. Wound nurses specializing in oncology wounds are invaluable.

Are there support groups for angiosarcoma?

Given its rarity, angiosarcoma-specific support groups are small but impactful. The Sarcoma Foundation of America and SARC (Sarcoma Alliance for Research through Collaboration) support angiosarcoma patients. Angiosarcoma Awareness organization provides disease-specific patient community. Online sarcoma communities on Facebook and Reddit include angiosarcoma patients who have found each other across geographic barriers.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.